Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00771849 | Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children | PHASE2 | COMPLETED | 103 | — | — | Aug 1, 2003 | May 1, 2004 | Apr 14, 2016 | 2 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Menactra® Vaccine Group | EXPERIMENTAL | Participants receiving the tetravalent (A, C, Y, and W 135) meningococcal diphtheria toxoid conjugate vaccine |
| Hiberix® Vaccine Group | ACTIVE_COMPARATOR | Participants receiving Haemophilus Influenzae Type b (Hib) vaccine |
| Name | Type | Description |
|---|---|---|
| Meningococcal Polysaccharide Diphtheria Toxoid Conjugate | BIOLOGICAL | 0.5 mL, Intramuscular |
| Haemophilus Influenzae Type b (Hib) vaccine | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria : * Participant is healthy, as determined by medical history and physical examination. * Participant is 2 years to \< 5 years of age at the time of vaccination. * At least one year from primary vaccination with a monovalent meningococcal C conjugate vaccine has elapsed. * Parent/...